UBS Group
LAB icon

UBS Group’s Standard BioTools LAB Stock Holding History

UBS Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$280K Buy
305,122
+40,717
+15% +$49.3K ﹤0.01% 6440
2025
Q4 		$338K Sell
264,405
-191,409
-42% -$257K ﹤0.01% 6285
2025
Q3 		$593K Buy
455,814
+77,943
+21% +$102K ﹤0.01% 5964
2025
Q2 		$453K Sell
377,871
-29,117
-7% -$32.3K ﹤0.01% 6087
2025
Q1 		$440K Buy
406,988
+3,835
+1% +$5.38K ﹤0.01% 5952
2024
Q4 		$706K Buy
403,153
+149,848
+59% +$279K ﹤0.01% 5602
2024
Q3 		$489K Buy
253,305
+77,769
+44% +$152K ﹤0.01% 5241
2024
Q2 		$311K Sell
175,536
-308,408
-64% -$754K ﹤0.01% 5372
2024
Q1 		$1.31M Buy
483,944
+462,722
+2,180% +$1.12M ﹤0.01% 4362
2023
Q4 		$46.9K Buy
21,222
+5,592
+36% +$11.9K ﹤0.01% 6567
2023
Q3 		$45.3K Sell
15,630
-3,160
-17% -$8.27K ﹤0.01% 6348
2023
Q2 		$36.3K Buy
18,790
+1,120
+6% +$2.21K ﹤0.01% 6638
2023
Q1 		$34.5K Sell
17,670
-14,801
-46% -$29.2K ﹤0.01% 6706
2022
Q4 		$38K Buy
32,471
+13,365
+70% +$16.5K ﹤0.01% 7017
2022
Q3 		$21K Sell
19,106
-10,344
-35% -$15.6K ﹤0.01% 7329
2022
Q2 		$47K Sell
29,450
-657,596
-96% -$1.63M ﹤0.01% 5966
2022
Q1 		$2.47M Sell
687,046
-38,119
-5% -$132K ﹤0.01% 3238
2021
Q4 		$2.84M Sell
725,165
-62,997
-8% -$295K ﹤0.01% 3416
2021
Q3 		$5.19M Sell
788,162
-6,969
-0.9% -$45.8K ﹤0.01% 2628
2021
Q2 		$4.9M Sell
795,131
-233,067
-23% -$1.25M ﹤0.01% 2708
2021
Q1 		$4.65M Buy
1,028,198
+451,502
+78% +$2.48M ﹤0.01% 2689
2020
Q4 		$3.46M Buy
576,696
+9,825
+2% +$64.5K ﹤0.01% 2847
2020
Q3 		$4.21M Sell
566,871
-386,543
-41% -$2.67M ﹤0.01% 2362
2020
Q2 		$3.82M Buy
953,414
+800,372
+523% +$2.79M ﹤0.01% 2260
2020
Q1 		$389K Buy
153,042
+45,959
+43% +$151K ﹤0.01% 4183
2019
Q4 		$373K Buy
107,083
+106,429
+16,274% +$374K ﹤0.01% 5096
2019
Q3 		$3K Sell
654
-2,249
-77% -$17.7K ﹤0.01% 7640
2019
Q2 		$36K Buy
2,903
+567
+24% +$7.22K ﹤0.01% 6187
2019
Q1 		$31K Sell
2,336
-7,140
-75% -$75.3K ﹤0.01% 5914
2018
Q4 		$82K Buy
9,476
+3,483
+58% +$27.1K ﹤0.01% 5705
2018
Q3 		$45K Buy
5,993
+2,547
+74% +$18.1K ﹤0.01% 6237
2018
Q2 		$21K Buy
3,446
+3,388
+5,841% +$19.3K ﹤0.01% 6656
2018
Q1 		$0 Sell
58
-2,341
-98% -$15.4K ﹤0.01% 8008
2017
Q4 		$14K Sell
2,399
-1,524
-39% -$8.34K ﹤0.01% 6805
2017
Q3 		$19K Buy
3,923
+3,415
+672% +$14.4K ﹤0.01% 6493
2017
Q2 		$2K Sell
508
-770
-60% -$3.65K ﹤0.01% 7377
2017
Q1 		$7K Sell
1,278
-3,982
-76% -$25.2K ﹤0.01% 6816
2016
Q4 		$39K Buy
5,260
+2,969
+130% +$18.6K ﹤0.01% 6020
2016
Q3 		$18K Sell
2,291
-4,424
-66% -$40.6K ﹤0.01% 6380
2016
Q2 		$61K Buy
6,715
+5,707
+566% +$53.6K ﹤0.01% 5372
2016
Q1 		$8K Sell
1,008
-2,176
-68% -$15.7K ﹤0.01% 6783
2015
Q4 		$34K Sell
3,184
-3,945
-55% -$38.7K ﹤0.01% 6209
2015
Q3 		$57K Buy
7,129
+3,883
+120% +$61.1K ﹤0.01% 5714
2015
Q2 		$79K Sell
3,246
-204
-6% -$6.44K ﹤0.01% 5598
2015
Q1 		$145K Buy
3,450
+1,362
+65% +$53.8K ﹤0.01% 5136
2014
Q4 		$70K Buy
+2,088
New +$59.1K ﹤0.01% 6067

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

UBS Group's LAB Position: Q1 2026 in Review

UBS Group increased its Standard BioTools (LAB) stake by 15% in Q1 2026, buying an estimated $49.3K and bringing the position to 305,122 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #6440.

UBS Group first reported a position in LAB in Q4 2014 and has held it in 46 quarters since. The position peaked at $5.19M in Q3 2021. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • UBS Group held 305,122 shares of Standard BioTools worth $280K as of Q1 2026.
  • UBS Group bought 40,717 Standard BioTools shares in Q1 2026, an estimated $49.3K.
  • Standard BioTools made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6440 holding.
  • UBS Group first reported a position in Standard BioTools in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Standard BioTools position peaked at $5.19M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.